Cornea

President and CEO of the International Keratoconus Academy Andrew Morgenstern, OD, FAAO, FNAP, shares some snippets about the live white paper development session and the patient Q&A happening at the inaugural IKA Keratoconus Symposium.

Co-founder of the International Keratoconus Academy S. Barry Eiden, OD, FAAO, FSLS, gives us the inside scoop on the inaugural IKA Keratoconus Symposium, which takes place this weekend in Scottsdale, Arizona.

Uri Soiberman, MD, shares some key takeaways from his presentation at the inaugural IKA Keratoconus Symposium.

The results showed that current smokers had a greater 5-year cumulative probability, compared with patients who had never smoked, of undergoing orbital decompression, strabismus surgery, and eyelid recession.

According to the company, KPI-012 could become the first approved treatment for persistent corneal epithelial defect across all its various etiologies.

The authors conducted a prospective non-interventional study in which a self-questionnaire was used to evaluate the ocular symptoms and medical background of patients with KC and OSD who engage in chronic eye rubbing.

An important take-away was the total and central corneal staining score improving after only 2 weeks of treatment.

Based on the initial ophthalmic findings, it is difficult but important to predict the patients’ progression to a specific level of disease severity.

Cochair Elizabeth Yeu, MD, highlights what this program will mean for ophthalmologists, optometrists, and their patients.

The primary outcome was an association between alcohol misuse and corneal endothelial metrics.

A look back on what happened in optometry during the week ofMarch 27-March 31.

Because the disease is vision-threatening, the investigators retrospectively reviewed the demographic, clinical, and surgical data from the cases of patients who required additional CXL.

Mitch Ibach, OD, FAOO, tells us about the current corneal cross-linking treatments, as well as those on the horizon.

Katie Gilbert-Spear, OD, JD, MPH, gives an overview on the importance of referring keratoconus patients to receive FDA-approved corneal cross-linking.

A look back on what's happened in optometry during the week of March 3-March 9.

Conference aims to promote professional education and scientific development in corneal ectasias.

A look back on what's happened in optometry during the week of February 25-March 2.

Andrew Morgenstern, OD, FAAO, FNAP, sits down to discuss the inaugural IKA Keratoconus Symposium in Scottsdale, Arizona, in April 2023.

A look back on what's happened in optometry during the week of February 18-February 23.

Eye care providers need to look beyond visual acuity in screening for keratoconus.

Loretta Szczotka-Flynn, OD, PhD, sits down to discuss the International Keratoconus Academy's first annual keratoconus symposium, which will be held April 22-23, 2023, in Scottsdale, Arizona.

Flavio Mantelli, MD, PhD, Chief Medical Officer at Dompé, shares about the company's role in nerve growth factor (NGF) applications in ophthalmic disease and other human indications.

CEO and cofounder of the International Keratoconus Academy S. Barry Eiden, OD, FAAO, FSLS, sits down to discuss the inaugural symposium, which will be held April 22-23, 2023, in Scottsdale, Arizona.

A wave of infections across 11 states have been linked to artificial tear use, leading to permanent vision loss, hospitalization, and one death.

The research team retrospectively studied the long-term corneal endothelial cell changes and visual outcomes after this iris-fixated phakic IOL was explanted in patients with endothelial damage and investigated any potential predictors of endothelial injury.

A look back on what's happened in optometry during the week of Jan. 7-Jan. 12, 2023.

Two novel, dropless technologies for keratoconus and dry eye disease make major advances with more to come later in 2023.

A recent study showed herpesvirus DNA in a high percentage of corneal grafts after transplantation.

Over the years, IKA has become an invaluable resource for eye care professionals.

In the second deal between Harrow and Novartis, the former is expected to add 5 ophthalmic products to its portfolio.